ストックスクリーナーアプリを入手
0.8488
1.53%
-0.0132
アフターアワーズ：
.85
0.0012
+0.14%
前日終値:
$0.862
開ける：
$0.859
24時間の取引高:
55,625
Relative Volume:
0.09
時価総額：
$22.97M
収益：
-
当期純損益:
$-1.40M
株価収益率:
-4.0926
EPS:
-0.2074
ネットキャッシュフロー:
$-10.49M
1週間 パフォーマンス:
+1.17%
1か月 パフォーマンス:
-27.45%
6か月 パフォーマンス:
-95.82%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.8341
$0.8949
1週間の範囲:
$0.8305
$0.9235
52週間の値動き範囲:
$0.614
$33.66
Liminatus Pharma Inc Stock (LIMN) Company Profile
LIMN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LIMN
Liminatus Pharma Inc
|
0.8488 | 23.33M | 0 | -1.40M | -10.49M | -0.2074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Liminatus Pharma Inc (LIMN) 最新ニュース
Contrasting Inhibikase Therapeutics (NASDAQ:IKT) & Liminatus Pharma (NASDAQ:LIMN) - Defense World
Investment Recap: Will Liminatus Pharma Inc stock benefit from AI adoptionPrice Action & AI Forecasted Entry and Exit Points - moha.gov.vn
Will Liminatus Pharma Inc. stock reach Wall Street targetsPortfolio Risk Summary & Daily Stock Trend Watchlist - Newser
What sentiment indicators say about Liminatus Pharma Inc. Equity Warrant stockEarnings Trend Report & Real-Time Buy Signal Alerts - Newser
Is Liminatus Pharma Inc. stock trading at a premium valuationTrade Risk Summary & Consistent Return Strategy Ideas - Newser
Chart Watch: Can TriCo Bancshares stock beat market expectations this quarterCPI Data & Daily Volume Surge Signals - BỘ NỘI VỤ
Reviewing Vor Biopharma (NASDAQ:VOR) and Liminatus Pharma (NASDAQ:LIMN) - Defense World
Will Liminatus Pharma Inc. Equity Warrant stock outperform Dow Jones indexPortfolio Gains Summary & Risk Controlled Daily Plans - moha.gov.vn
Can Liminatus Pharma Inc. stock outperform in 2025 bull marketEarnings Risk Report & Growth Focused Entry Reports - moha.gov.vn
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Liminatus Pharma Faces Nasdaq Non-Compliance Notice - MSN
Is Liminatus Pharma Inc. stock in correction or buying zoneJuly 2025 Short Interest & Safe Entry Momentum Tips - moha.gov.vn
Liminatus Pharma receives Nasdaq notice for non-compliance with listing standards - Investing.com
LIMN gets Nasdaq warnings over market value and listing rules - Stock Titan
Holdings of Chegg Inc (CHGG) are aligned with the stars - Setenews
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Views of Wall Street’s Leading Experts on Liminatus Pharma Inc - Setenews
Published on: 2025-11-24 07:40:26 - earlytimes.in
What analysts say about Liminatus Pharma Inc Equity Warrant stockTechnology Stock Trends & Free Get High Impact Recommendations - earlytimes.in
Liminatus Pharma (NASDAQ:LIMN) versus Prime Medicine (NASDAQ:PRME) Head to Head Comparison - Defense World
Liminatus Pharma (NASDAQ:LIMN) Downgraded by Wall Street Zen to Strong Sell - Defense World
Midday Stock Roundup: RxSight up 14% - Orange County Business Journal
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Liminatus Pharma, Inc. Class A Common Stock (LIMN) -29.6% in Normal Trading: Significant Drop Amid Routine Trading - Stocks Telegraph
Dow Surges Over 200 Points; BJ's Wholesale Posts Upbeat Q3 Earnings - Sahm
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Is Liminatus Pharma Inc. Equity Warrant stock a defensive play in 2025Earnings Miss & Low Drawdown Trading Techniques - newser.com
Why Liminatus Pharma Inc. Equity Warrant stock attracts high net worth investorsPortfolio Update Report & Reliable Price Breakout Alerts - newser.com
Prime Medicine (NASDAQ:PRME) and Liminatus Pharma (NASDAQ:LIMN) Critical Review - Defense World
Is Liminatus Pharma Inc. stock recession proof2025 Buyback Activity & Fast Gain Swing Alerts - newser.com
Signal strength of Liminatus Pharma Inc. stock in tech scannersJuly 2025 EndofMonth & Fast Exit and Entry Strategy Plans - newser.com
Will Liminatus Pharma Inc. Equity Warrant stock deliver strong dividend growthJuly 2025 Catalysts & Weekly Chart Analysis and Guides - newser.com
Why Liminatus Pharma Inc. Equity Warrant stock is seen as undervaluedQuarterly Portfolio Summary & AI Powered Market Entry Ideas - newser.com
Backtesting results for Liminatus Pharma Inc. trading strategies2025 Technical Patterns & Real-Time Volume Analysis Alerts - newser.com
How to use Fibonacci retracement on Liminatus Pharma Inc. Equity WarrantMarket Performance Summary & Capital Protection Trade Alerts - newser.com
Is Liminatus Pharma Inc. Equity Warrant forming a bottoming baseQuarterly Portfolio Review & Fast Gaining Stock Reports - newser.com
Multi factor analysis applied to Liminatus Pharma Inc.July 2025 Gainers & Weekly Sector Rotation Insights - newser.com
Is Liminatus Pharma Inc. stock entering bullish territoryJuly 2025 Rallies & Low Drawdown Trading Strategies - newser.com
What risks investors should watch in Liminatus Pharma Inc. Equity Warrant stock2025 Dividend Review & Fast Momentum Stock Entry Tips - newser.com
Analyzing recovery setups for Liminatus Pharma Inc. Equity Warrant investors2025 Support & Resistance & Free Technical Pattern Based Buy Signals - newser.com
[At the Crossroads] Ewha Compotech ④ Unable to Receive Liminatus Shares for 6 Months... Only Suspicious Funds Reaped Gains - 아시아경제
Contrasting Prime Medicine (NASDAQ:PRME) & Liminatus Pharma (NASDAQ:LIMN) - Defense World
Analyzing Prime Medicine (NASDAQ:PRME) and Liminatus Pharma (NASDAQ:LIMN) - Defense World
Is Liminatus Pharma Inc. showing signs of accumulationIndex Update & Weekly Top Stock Performers List - newser.com
[At a Crossroads] Ewha Compotech③ Capital Erosion Begins Amid 'Liminatus Pharma' Losses - 아시아경제
Using data models to predict Liminatus Pharma Inc. Equity Warrant stock movementWeekly Gains Report & Entry Point Strategy Guides - newser.com
Liminatus Pharma Inc (LIMN) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):